XUPB Stock Overview
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Genfit S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.12 |
| 52 Week High | €4.24 |
| 52 Week Low | €2.72 |
| Beta | 0.87 |
| 1 Month Change | -5.45% |
| 3 Month Change | -9.83% |
| 1 Year Change | -8.77% |
| 3 Year Change | -13.33% |
| 5 Year Change | n/a |
| Change since IPO | -28.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| XUPB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.6% | -0.2% | 0.5% |
| 1Y | -8.8% | -22.8% | 1.3% |
Price Volatility
| XUPB volatility | |
|---|---|
| XUPB Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XUPB has not had significant price volatility in the past 3 months.
Volatility Over Time: XUPB's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 159 | M. Prigent | www.genfit.com |
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Genfit S.A. Fundamentals Summary
| XUPB fundamental statistics | |
|---|---|
| Market cap | €157.09m |
| Earnings (TTM) | -€28.89m |
| Revenue (TTM) | €34.48m |
4.6x
P/S Ratio-5.4x
P/E RatioIs XUPB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XUPB income statement (TTM) | |
|---|---|
| Revenue | €34.48m |
| Cost of Revenue | €0 |
| Gross Profit | €34.48m |
| Other Expenses | €63.38m |
| Earnings | -€28.89m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 19, 2024
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 100.00% |
| Net Profit Margin | -83.79% |
| Debt/Equity Ratio | 94.6% |
How did XUPB perform over the long term?
See historical performance and comparison